# International Nonproprietary Names for Pharmaceutical Substances (INN)

Notice is hereby given that, in accordance with article 3 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances, the following names are under consideration by the World Health Organization as Proposed International Nonproprietary Names. The inclusion of a name in the lists of Proposed International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Comments on, or formal objections to, the proposed names may be forwarded by any person to the INN Programme of the World Health Organization within four months of the date of their publication in *WHO Drug Information*, i.e., for **List 70 Proposed INN not later than 30 June 1994.**

## Proposed International Nonproprietary Names: List 70

*Lists of proposed (1–65) and recommended (1–31) international nonproprietary names can be found in Cumulative List No. 8, 1992.*

| *Proposed International Nonproprietary Name (Latin, English)* | *Chemical Name or Description; Molecular and Graphic formulae Chemical Abstracts Service (CAS) registry number Action and Use** |
|---|---|
| abciximabum<br>abciximab | immunoglobulin G (human-mouse monoclonal c7E3 clone p7E3$V_H$h$C_{γ4}$ Fab fragment anti-human glycoprotein IIb/IIIa receptor), disulfide with human-mouse monoclonal c7E3 clone p7E3$V_K$h$C_K$ light chain<br>143653-53-6 *antithrombotic* |
| acidum incadronicum<br>incadronic acid | [(cycloheptylamino)methylene]diphosphonic acid<br>$C_8H_{19}NO_6P_2$ 124351-85-5 *calcium regulator*<br>  |
| adatanserinum<br>adatanserin | *N*-[2-[4-(2-pyrimidinyl)-1-piperazinyl]ethyl]-1-adamantanecarboxamide<br>$C_{21}H_{31}N_5O$ 127266-56-2 *serotonin receptor antagonist*<br>  |

***Action and Use:** The statements in italics indicating the action and use are based largely on information supplied by the manufacturer. The information is meant to provide an indication of the potential use of new substances at the time they are accorded Proposed International Nonproprietary Names. WHO is not in a position either to uphold these statements or to comment on the efficacy of the action claimed. Because of their provisional nature, these descriptors will be neither revised nor included in the Cumulative Lists of INNs.*

| *Proposed International Nonproprietary Name (Latin, English)* | *Chemical Name or Description; Molecular and Graphic formulae Chemical Abstracts Service (CAS) registry number Action and Use** |
|---|---|
| adelmidrolum<br>adelmidrol | *N,N'*-bis(2-hydroxyethyl)nonanediamide<br>$C_{13}H_{26}N_2O_4$ 1675-66-7 *antiacne agent*<br>  |
| afovirsenum<br>afovirsen | 2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thioguanylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thioadenylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-2'-deoxy-*P*-thiocytidylyl-(5'→3')-2'-deoxy-*P*-thioguanylyl-(5'→3')-*P*-thiothymidylyl-(5'→3')-thymidine<br>$C_{192}H_{250}N_{57}O_{107}P_{19}S_{19}$ *antiviral* |
| aglepristonum<br>aglepristone | 11β-[*p*-(dimethylamino)phenyl]-17β-hydroxy-17-[(*Z*)-propenyl]estra-4,9-dien-3-one<br>$C_{29}H_{37}NO_2$ 124478-60-0 *abortive (vet.)*<br>  |
| alnespironum<br>alnespirone | (+)-(*S*)-*N*-[4-[(5-methoxy-3-chromanyl)propylamino]butyl]-1,1-cyclopentanediacetimide<br>$C_{26}H_{38}N_2O_4$ 138298-79-0 *antidepressant*<br>  |
| arteflenum<br>arteflene | (1*S*,4*R*,5*R*,8*S*)-4-[(*Z*)-2,4-bis(trifluoromethyl)styryl]-4,8-dimethyl-2,3-dioxabicyclo[3.3.1]nonan-7-one<br>$C_{19}H_{18}F_6O_3$ 123407-36-3 *antimalarial*<br>  |

| *Proposed International Nonproprietary Name (Latin, English)* | *Chemical Name or Description, Molecular and Graphic formulae Chemical Abstracts Service (CAS) registry number Action and Use** |
|---|---|
| batimastatum<br>batimastat | (2*S*,3*R*)-5-methyl-3-[[(α*S*)-α-(methylcarbamoyl)phenethyl]carbamoyl]-2-[(2-thienylthio)methyl]hexanohydroxamic acid<br>$C_{23}H_{31}N_3O_4S_2$ 130370-60-4 *antineoplastic*<br>  |
| besipirdinum<br>besipirdine | 1-(propyl-4-pyridylamino)indole<br>$C_{16}H_{17}N_3$ 119257-34-0 *nootropic agent*<br>  |
| bicalutamidum<br>bicalutamide | (±)-4'-cyano-α,α,α-trifluoro-3-[(*p*-fluorophenyl)sulfonyl]-2-methyl-*m*-lactotoluidide<br>$C_{18}H_{14}F_4N_2O_4S$ 90357-06-5 *antiandrogen*<br>  **and enantiomer** |
| bosentanum<br>bosentan | *p-tert*-butyl-*N*-[6-(2-hydroxyethoxy)-5-(*o*-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide<br>$C_{27}H_{29}N_5O_6S$ 147536-97-8 *endothelin receptor antagonist*<br>  |
| candocuronii iodidum<br>candocuronium iodide | 17a,17a-dimethyl-3β-(1-methylpyrrolidinio)-17a-azonia-*D*-homoandrost-5-ene diiodide<br>$C_{28}H_{46}I_2N_2$ 54278-85-2 *neuromuscular receptor antagonist*<br>  |
| capromabum<br>capromab | immunoglobulin G 1 (mouse monoclonal 7E11-C5 3 anti-human prostatic carcinoma cell), disulfide with mouse monoclonal 7E11-C5.3 light chain, dimer<br>151763-64-3 *diagnostic agent* |

| *Proposed International Nonproprietary Name (Latin, English)* | *Chemical Name or Description: Molecular and Graphic formulae Chemical Abstracts Service (CAS) registry number Action and Use** |
|---|---|
| certoparinum natricum<br>certoparin sodium | Sodium salt of depolymerized heparin obtained by isoamyl nitrite degradation of heparin from pork intestinal mucosa; the majority of the components have a 2-*O*-sulfo-α-L-idopyranosuronic acid structure at the non reducing end and a 6-*O*-sulfo-2,5-anhydro-D-mannose structure at the reducing end of their chain; the average relative molecular mass is 5000 to 7000; at least 70 per cent less than 10 000: the degree of sulfatation is 2 to 2,5 per disaccharidic unit.<br>*anticoagulant* |
| cinalukastum<br>cinalukast | 3'-[(*E*)-2-(4-cyclobutyl-2-thiazolyl)vinyl]-2,2-diethylsuccinanilic acid<br>$C_{23}H_{28}N_2O_3S$ 128312-51-6 *antiasthmatic*<br>  |
| dapabutanum<br>dapabutan | (±)-3-[[3-(dodecylamino)propyl]amino]butyric acid<br>$C_{19}H_{40}N_2O_2$ 6582-31-6 *antiseptic*<br>  |
| darifenacinum<br>darifenacin | (*S*)-1-[2-(2,3-dihydro-5-benzofuranyl)ethyl]-α,α-diphenyl-3-pyrrolidineacetamide<br>$C_{28}H_{30}N_2O_2$ 133099-04-4 *muscarin receptor antagonist*<br>  |
| denotivirum<br>denotivir | 5-benzamido-4'-chloro-3-methyl-4-isothiazolecarboxanilide<br>$C_{18}H_{14}ClN_3O_2S$ 51287-57-1 *antiviral*<br>  |
| desirudinum<br>desirudin | 63-desulfohirudin (*Hirudo medicinalis* isoform HV2)<br>$C_{287}H_{440}N_{80}O_{110}S_6$ 120993-53-5 *anticoagulant* |
| desmeninolum<br>desmeninol | (±)-2-hydroxy-4-(methylthio)butyric acid<br>$C_5H_{10}O_3S$ 120-91-2 *amino acid analogue*<br>  and enantiomer |
| detumomabum<br>detumomab | immunoglobulin (mouse monoclonal SPECIFID anti-human B lymphoma cell) disulfide with mouse monoclonal SPECIFID light chain, dimer<br>145832-33-3 *immunomodulator* |

| *Proposed International Nonproprietary Name (Latin. English)* | *Chemical Name or Description; Molecular and Graphic formulae Chemical Abstracts Service (CAS) registry number Action and Use** |
|---|---|
| dexketoprofenum<br>dexketoprofen | (+)-(*S*)-*m*-benzoylhydratropic acid<br>$C_{16}H_{14}O_3$ 22161-81-5 *non-steroidal anti-inflammatory, analgesic*<br>  |
| dornasum alfa<br>dornase alfa | deoxyribonuclease (human clone 18-1 protein moiety)<br>$C_{1321}H_{1995}N_{339}O_{396}S_8$ 143831-71-4 *enzyme* |
| elopiprazolum<br>elopiprazole | 1-(7-benzofuranyl)-4-[[5-(*p*-fluorophenyl)pyrrol-2-yl]methyl]piperazine<br>$C_{23}H_{22}FN_3O$ 115464-77-2 *antipsychotic*<br>  |
| emideltidum<br>emideltide | L-tryptophyl-L-alanylglycylglycyl-L-α-aspartyl-L-alanyl-L-serylglycyl-L-glutamic acid<br>$C_{35}H_{48}N_{10}O_{15}$ 62568-57-4 *sedative*<br>H–Trp–Ala–Gly–Gly–Asp–Ala–Ser–Gly–Glu–OH |
| enlimomabum<br>enlimomab | immunoglobulin G 2a (mouse monoclonal BI-RR-1 anti-human-antigen CD 54), disulfide with mouse monoclonal BI-RR-1 light chain, dimer<br>142864-19-5 *immunomodulator* |
| geclosporinum<br>geclosporin | cyclo[[(2*S*,3*R*,4*R*,6*E*)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-norvalyl-*N*-methylglycyl-*N*-methyl-L-leucyl-L-valyl-*N*-methyl-L-leucyl-L-alanyl-D-alanyl-*N*-methyl-L-leucyl-*N*-methyl-L-leucyl-*N*-methyl-L-valyl]<br>$C_{63}H_{113}N_{11}O_{12}$ 74436-00-3 *immunosuppressant*<br>  |

| *Proposed International Nonproprietary Name (Latin, English)* | *Chemical Name or Description; Molecular and Graphic formulae Chemical Abstracts Service (CAS) registry number Action and Use** |
|---|---|
| glenvastatinum<br>glenvastatin | (4*R*,6*S*)-6-[(*E*)-2-[4-(*p*-fluorophenyl)-2-isopropyl-6-phenyl-3-pyridyl]vinyl]tetrahydro-4-hydroxy-2*H*-pyran-2-one<br>$C_{27}H_{26}FNO_3$ 122254-45-9 *antihyperlipidaemic* |
| |  |
| icometasonii enbutas<br>icometasone enbutate | 9-chloro-11β,17,21-trihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17-butyrate 21-acetate<br>$C_{28}H_{37}ClO_7$ 103466-73-5 *corticosteroid* |
| |  |
| iganidipinum<br>iganidipine | (±)-3-(4-allyl-1-piperazinyl)-2,2-dimethylpropyl methyl 1,4-dihydro-2,6-dimethyl-4-(*m*-nitrophenyl)-3,5-pyridinedicarboxylate<br>$C_{28}H_{36}N_4O_6$ 119687-33-1 *calcium channel blocker* |
| |  |
| ilepcimidum<br>ilepcimide | 1-[(*E*)-3,4-(methylenedioxy)cinnamoyl]piperidine<br>$C_{15}H_{17}NO_3$ 82857-82-7 *anticonvulsant* |
| |  |
| ilonidapum<br>ilonidap | 6-chloro-5-fluoro-3-[(*Z*)-α-hydroxy-2-thenylidene]-2-oxo-1-indolinecarboxamide<br>$C_{14}H_9ClFN_2O_3S$ 135202-79-8 *non-steroidal anti-inflammatory* |
| |  |

| *Proposed International Nonproprietary Name (Latin, English)* | *Chemical Name or Description; Molecular and Graphic formulae Chemical Abstracts Service (CAS) registry number Action and Use** |
|---|---|
| imitrodastum<br>imitrodast | 4,5-dihydro-2-(imidazol-1-ylmethyl)benzo[*b*]thiophene-6-carboxylic acid<br>$C_{13}H_{12}N_2O_2S$ 114686-12-3 *antiasthmatic, thromboxane $A_2$ synthetase inhibitor* |
| |  |
| iralukastum<br>iralukast | 7-[[(1*S*,2*E*,4*Z*)-9-(4-acetyl-3-hydroxy-2-propylphenoxy)-1-[(α*R*)-α-hydroxy-*m*-(trifluoromethyl)benzyl]-2,4-nonadienyl]thio]-4-oxo-4*H*-1-benzopyran-2-carboxylic acid<br>$C_{38}H_{37}F_3O_8S$ 151581-24-7 *antiasthmatic* |
| |  |
| laflunimusum<br>laflunimus | (*Z*)-α-cyano-$\alpha^{4'},\alpha^{4'},\alpha^{4'}$-trifluoro-β-hydroxycyclopropaneacrylo-3',4'-xylidide<br>$C_{15}H_{13}F_3N_2O_2$ 147076-36-6 *immunodepressant* |
| |  |
| lafutidinum<br>lafutidine | (±)-2-(furfurylsulfinyl)-*N*-[(*Z*)-4-[[4-(piperidinomethyl)-2-pyridyl]oxy]-2-butenyl]= acetamide<br>$C_{22}H_{29}N_3O_4S$ 118288-08-7 *histamine $H_2$-receptor antagonist* |
| |  |
| laurcetii bromidum<br>laurcetium bromide | (carboxymethyl)dodecyldimethylammonium bromide, ethyl ester<br>$C_{18}H_{38}BrNO_2$ 1794-75-8 *antiseptic* |
| |  |
| lecimibidum<br>lecimibide | 3-(2,4-difluorophenyl)-1-[5-[(4,5-diphenylimidazol-2-yl)thio]pentyl]-1-heptylurea<br>$C_{34}H_{40}F_2N_4OS$ 130804-35-2 *antihyperlipidaemic* |
| |  |

| *Proposed International Nonproprietary Name (Latin, English)* | *Chemical Name or Description; Molecular and Graphic formulae Chemical Abstracts Service (CAS) registry number Action and Use** |
|---|---|
| ledismasum<br>ledismase | superoxide dismutase (human copper-zinc subunit), cyclic (57→146)-disulfide, dimer<br>$C_{679}H_{1063}N_{203}O_{224}S_4$ 149394-67-2 *enzyme* |
| lemoxinolum<br>lemoxinol | α-(4,6-dichloro-*m*-tolyl)oxy-ω-hydroxypoly(oxyethylene)<br>Each *lemoxinol* name is followed by a number indicating the approximate number of oxyethylene groups present, e.g. *lemoxinol 5*, and the individual chemical names may contain a specific numerical syllable for the same purpose<br>$C_7H_6OCl_2(C_2H_4O)_n$ *antiseptic*<br>  |
| letrozolum<br>letrozole | 4,4'-(1*H*-1,2,4-triazol-1-ylmethylene)dibenzonitrile<br>$C_{17}H_{11}N_5$ 112809-51-5 *antineoplastic*<br>  |
| lexipafantum<br>lexipafant | *N*-methyl-*N*-[[α-(2-methyl-1*H*-imidazo[4,5-*c*]pyridin-1-yl)-*p*-tolyl]sulfonyl]-L-leucine, ethyl ester<br>$C_{23}H_{30}N_4O_4S$ 139133-26-9 *platelet activating factor antagonist*<br>  |
| lopobutanum<br>lopobutan | (±)-3-[[3-(dodecyloxy)propyl]amino]butyric acid<br>$C_{19}H_{39}NO_3$ 6582-30-5 *antiseptic*<br>  |
| loviridum<br>loviride | (±)-2-(6-acetyl-*m*-toluidino)-2-(2,6-dichlorophenyl)acetamide<br>$C_{17}H_{16}Cl_2N_2O_2$ 147362-57-0 *antiviral*<br>  and enantiomer |

| *Proposed International Nonproprietary Name (Latin, English)* | *Chemical Name or Description; Molecular and Graphic formulae Chemical Abstracts Service (CAS) registry number Action and Use** |
|---|---|
| lubeluzolum<br>lubeluzole | (+)-(*S*)-4-(2-benzothiazolylmethylamino)-α-[(3,4-difluorophenoxy)methyl]-1-piperidineethanol<br>$C_{22}H_{25}F_2N_3O_2S$ 144665-07-6 *neural protective agent* |
| |  |
| mofarotenum<br>mofarotene | 4-[2-[*p*-[(*E*)-2-(5,6,7,8-tetrahydro-5 5.8,8-tetramethyl-2-naphthyl)propenyl]=phenoxy]ethyl]morpholine<br>$C_{29}H_{39}NO_2$ 125533-88-2 *antineoplastic* |
| |  |
| nupafantum<br>nupafant | *N*-[(*S*)-1-(ethoxymethyl)-3-methylbutyl]-*N*-methyl-α-(2-methyl-1*H*-imidazo[4,5-*c*]pyridin-1-yl)-*p*-toluenesulfonamide<br>$C_{23}H_{32}N_4O_3S$ 139133-27-0 *platelet activating factor antagonist* |
| |  |
| olprinonum<br>olprinone | 1,2-dihydro-5-imidazo[1,2-*a*]pyridin-6-yl-6-methyl-2-oxonicotinonitrile<br>$C_{14}H_{10}N_4O$ 106730-54-5 *cardiac stimulant, vasodilator* |
| |  |

oxeclosporinum
oxeclosporin

cyclo[[(2*S*,3*R*,4*R*,6*E*)-3-hydroxy-4-methyl-2-(methylamino)-6-octenoyl]-L-2-aminobutyryl-*N*-methylglycyl-*N*-methyl-L-leucyl-L-valyl-*N*-methyl-L-leucyl-L-alanyl-*O*-(2-hydroxyethyl)-D-seryl-*N*-methyl-L-leucyl-*N*-methyl-L-leucyl-*N*-methyl-L-valyl]
$C_{64}H_{115}N_{11}O_{14}$ 135548-15-1 *immunosuppressant*



pamicogrelum
pamicogrel

ethyl 2-[4,5-bis(*p*-methoxyphenyl)-2-thiazolyl]pyrrole-1-acetate
$C_{25}H_{24}N_2O_4S$ 101001-34-7 *platelet aggregation inhibitior*



pazinaclonum
pazinaclone

(±)-8-[[2-(7-chloro-1,8-naphthyridin-2-yl)-3-oxo-1-isoindolinyl]acetyl]-1,4-dioxa-8-azaspiro[4 5]decane
$C_{25}H_{23}ClN_4O_4$ 103255-66-9 *anxiolytic*



and enantiomer

pobilukastum
pobilukast

(2*S*,3*R*)-3-[(2-carboxyethyl)thio]-3-[*o*-(8-phenyloctyl)phenyl]lactic acid
$C_{26}H_{34}O_5S$ 107023-41-6 *antiasthmatic,leukotriene receptor antagonist*



| *Proposed International Nonproprietary Name (Latin, English)* | *Chemical Name or Description, Molecular and Graphic formulae Chemical Abstracts Service (CAS) registry number Action and Use** |
|---|---|
| polixetonii chloridum<br>polixetonium chloride | poly[oxyethylene(dimethyliminio)ethylene(dimethyliminio)ethylene dichloride]<br>$(C_{10}H_{24}Cl_2N_2O)_n$ 31512-74-0 *disinfectant* |
| |  |
| ramosetronum<br>ramosetron | (–)-(*R*)-1-methylindol-3-yl 4,5,6,7-tetrahydro-5-benzimidazolyl ketone<br>$C_{17}H_{17}N_3O$ 132036-88-5 *serotonin receptor antagonist* |
| |  |
| rasagilinum<br>rasagiline | (*R*)-*N*-2-propynyl-1-indanamine<br>$C_{12}H_{13}N$ 136236-51-6 *antiparkinsonian* |
| |  |
| ricasetronum<br>ricasetron | 3,3-dimethyl-*N*-1α*H*,5α*H*-tropan-3α-yl-1-indolinecarboxamide<br>$C_{19}H_{27}N_3O$ 117086-68-7 *serotonin receptor antagonist* |
| |  |
| seratrodastum<br>seratrodast | (±)-2,4.5-trimethyl-3,6-dioxo-ζ-phenyl-1,4-cyclohexadiene-1-heptanoic acid<br>$C_{22}H_{26}O_4$ 112665-43-7 *antiasthmatic. thromboxane $A_2$ receptor antagonist* |
| |  |
| spiroglumidum<br>spiroglumide | (*R*)-γ-(3,5-dichlorobenzamido)-δ-oxo-8-azaspiro[4.5]decane-8-valeric acid<br>$C_{21}H_{26}Cl_2N_2O_4$ 137795-35-8 *antiulcer* |
| |  |

| *Proposed International Nonproprietary Name (Latin, English)* | *Chemical Name or Description; Molecular and Graphic formulae Chemical Abstracts Service (CAS) registry number Action and Use** |
|---|---|
| sprodiamidum<br>sprodiamide | aqua[*N*,*N*-bis[2-[(carboxymethyl)[(methylcarbamoyl)methyl]amino]ethyl]= glycinato(3-)]dysprosium, hydrate<br>$C_{16}H_{28}DyN_5O_9 \cdot xH_2O$ 138721-73-0 *diagnostic aid* |



technetium ($^{99m}$Tc) furifosminum
technetium ($^{99m}$Tc) furifosmin

(*OC*-6-13)-[[4,4'-[ethylenebis(nitrilomethylidyne)]bis[dihydro-2,2,5,5-tetramethyl-3(2*H*)-furanonato]](2-)-*N*,*N*',$O^3$,$O^{3'}$]bis[tris(3-methoxypropyl)phosphine-*P*][$^{99m}$Tc]= technetium(1+) chloride
$C_{44}H_{84}ClN_2O_{10}P_2{}^{99m}Tc$ 142481-95-6 *radiocontrast medium*



telmisartanum
telmisartan

4'-[[4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl]methyl]-2-biphenylcarboxylic acid
$C_{33}H_{30}N_4O_2$ 144701-48-4 *angiotensin II receptor antagonist*



temoporfinum
temoporfin

3,3',3",3"'-(7,8-dihydroporphyrin-5,10,15,20-tetrayl)tetraphenol
$C_{44}H_{32}N_4O_4$ 122341-38-2 *photosensitizer*



tisartanum
tisartan

1-[[*N*-[*p*-(*o*-1*H*-tetrazol-5-ylphenyl)benzyl]valeramido]methyl]-1-cyclopentane-carboxylic acid
$C_{26}H_{31}N_5O_3$ 137882-98-5 *angiotensin II receptor antagonist*



tolafentrinum
tolafentrine

(–)-4'-(*cis*-1,2,3,4,4a,10b-hexahydro-8,9-dimethoxy-2-methylbenzo[*c*][1,6]-naphthyridin-6-yl)-*p*-toluenesulfonanilide
$C_{28}H_{31}N_3O_4S$ 139308-65-9 *phosphodiesterase-inhibitor*



tradecamidum
tradecamide

13-hydroxy-*N*,*N*-dimethyltridecanamide
$C_{15}H_{31}NO_2$ 132787-19-0 *antiacne agent*



votumumabum
votumumab

immunoglobulin G3 (human monoclonal 88-BV59 heavy chain anti-human carcinoma-associated antigen), disulfide with human monoclonal 88-BV59 κ-chain, dimer
148189-70-2 *diagnostic agent*

xanomelinum
xanomeline

3-[4-(hexyloxy)-1,2,5-thiadiazol-3-yl]-1,2,5,6-tetrahydro-1-methylpyridine
$C_{14}H_{23}N_3OS$ 131986-45-3 *cholinergic*



zankirenum
zankiren

(*S*)-*N*-[(1*S*,2*R*,3*S*)-1-(cyclohexylmethyl)-2,3-dihydroxy-5-methylhexyl]-α-[(α*S*)-α-[[(4-methyl-1-piperazinyl)sulfonyl]methyl]hydrocinnamamido]-4-thiazole=propionamide
$C_{35}H_{55}N_5O_6S_2$ 138742-43-5 *antihypertensive*



zolasartanum
zolasartan

1-[[3-bromo-2-(*o*-1*H*-tetrazol-5-ylphenyl)-5-benzofuranyl]methyl]-2-butyl-4-chloroimidazole-5-carboxylic acid
$C_{24}H_{20}BrClN_6O_3$ 145781-32-4 *angiotensin II receptor antagonist*



## Names for Radicals and Groups

Some substances for which a proposed international nonproprietary name has been established may be used in the form of salts or esters. The radicals or groups involved may be of complex composition and it is then inconvenient to refer to them in systematic chemical nomenclature. Consequently, shorter nonproprietary names for some radicals and groups have been devised or selected, and they are suggested for use with the proposed international nonproprietary names.

dapropas
dapropate

*N*,*N*-dimethyl-β-alanine
$C_5H_{10}NO_2$



edaminum
edamine

ethylene diamine
$C_2H_8N_2$



fostedatum
fostedate

tetradecyl hydrogen phosphate
$C_{14}H_{30}O_4P$



## AMENDMENTS TO PREVIOUS LISTS

Supplement to WHO Chronicle Vol. 36, No. 5, 1982

### Proposed International Nonproprietary Names (Prop. INN): List 48

p. 14 mitindomidum
mitindomide

*replace the chemical name, and the graphic formula by the following:*

(1*R**,2*S**,3*R**.4*S**,5*R**,6*S**,7*S**,8*R**)-tricyclo[4.2.2.0$^{2,5}$]dec-9-ene-3,4,7,8-tetracarboxylic 3,4:7,8-diimide



WHO Drug Information, Vol. 4. No. 2, 1990

### Proposed International Nonproprietary Names (Prop. INN): List 63

p. 6 gadodiamidum
gadodiamide

*replace the chemical name. CAS registry number, the molecular formula and the graphic formula by the following:*

[*N*,*N*-bis[2-[(carboxymethyl)[methylcarbamoyl)methyl]amino]ethyl]glycinato=(3-)]gadolinium
$C_{16}H_{26}GdN_5O_8$ 131410-48-5



WHO Drug Information, Vol 4. No. 4, 1990

### Proposed International Nonproprietary Names (Prop. INN): List 64

p. 12 gadoteridolum
gadoteridol

*replace the chemical name by the following:*

(±)-[10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetato=[(3-)]gadolinium

WHO Drug Information, Vol 6. No. 2, 1992

### Proposed International Nonproprietary Names (Prop. INN): List 67

p. 12 pendetidum
pendetide

*add the following CAS registry number:*

148805-91-8

## Proposed International Nonproprietary Names (Prop. INN): List 68

p 7 igmesinum
igmesine

*replace the action and use statement by the following:*

σ *ligand*

p 15 docetaxelum
docetaxel

*replace the chemical name, CAS registry number and the graphic formula by the following:*

(2*R*,3*S*)-*N*-carboxy-3-phenylisoserine, *N*-*tert*-butyl ester, 13-ester with 5β-20-epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate, trihydrate

148408-66-6




### Procedure and Guiding Principles

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will from now on be reproduced in uneven numbers of proposed INN lists only.